BACKGROUND
At present, there are many clinical markers and models to assess ovarian reserve, but none of them are ideal. The number of clinical samples is a key factor limiting the specificity and sensitivity of the markers and models, and traditional methods of subject recruitment are time and vigor. In addition, the model of ovarian reserve assessment for Chinese women need to be further explored.
OBJECTIVE
To explore the possibility of self-reporting for subjects through the WeChat mini program, and provide more data support for further optimization of the OvAge model, and to develop a predictive model of ovarian reserve that is specific to Chinese women.
METHODS
In this paper, with reference to the existing OvAge model, we developed an online OvAge calculator based on the WeChat mini program for data collection, and then applied the generalized linear model theory to obtain a predictive model of ovarian reserve which is in line with the characteristics of Chinese women.
RESULTS
Compared to traditional recruiting methods, the online OvAge calculator is able to collect a large number of samples in a short period of time, which is efficient and convenient. Optimized model of estimated OvAge =exp (3.5254-0.001*PRL-0.0231*AMH). This model showed a high statistical significance for each marker included in the equation. We applied the final equation on diminished ovarian reserve and polycystic ovary syndrome datasets and obtained a mean of predicted ovarian age significantly different from the mean of chronological age in both groups.
CONCLUSIONS
The OvAge calculator based on the WeChat mini program is a novel online subject self-reporting system that can collect many samples in a short period of time, continuously optimize the model and update the mini program version, which is economical, time-saving and efficient., and is worthy of promotion. In addition, the optimized OvAge model is suitable for Chinese women and provides a reference for clinical assessment of ovarian reserve.
CLINICALTRIAL
The study was approved by Chinese Clinical Trial Registry (registration No. ChiCTR2000037522) and Medical ethics committee of Jiangsu Province Hospital of Chinese Medicine (approved No. 2019NL-152-02).